Asylia Diagnostics is a precision medicine theranostics company. We integrate AI and real-world evidence data and transform heterogeneous patient populations into well-defined subgroups that share common molecular and immuno-pathophysiology profiles. By doing this we are able to identify highly specific biomarkers and drug targets. We then activate these targets using histone-modifying CRISPR/Cas9 gene-editing technology. By combining AI, RWE and gene editing we turn non-responding patients into responders and bring transformative precision medicine solutions to patients in need

We are targeting auto-immune and cancer disorders and starting with metastatic melanoma, NSCLC, head and neck cancer, SLE, and systemic sclerosis. Since company formation in 2019, we have achieved excellent scientific and business traction: we are on track to secure partnerships with the largest IVD and pharma partners. With a stellar strong team of founders-scientists and advisors, we are on the journey to deliver truly transformative therapies for patients in need.